Personalis (NasdaqGM:PSNL) - Share price, News & Analysis

PSNL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

PSNL Stock Overview

Personalis, Inc. operates as a cancer genomics company worldwide.

Rewards

Revenue is forecast to grow 28.21% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year

Personalis Competitors

Compugen

NasdaqGM:CGEN

US$167.7m

ChromaDex

NasdaqCM:CDXC

US$122.6m

Standard BioTools

NasdaqGS:LAB

US$139.1m

Harvard Bioscience

NasdaqGM:HBIO

US$155.5m

Price History & Performance

Summary of all time highs, changes and price drops for Personalis
Historical stock prices
Current Share Price	US$3.68
52 Week High	US$28.28
52 Week Low	US$3.13
Beta	1.74
1 Month Change	-19.65%
3 Month Change	-55.77%
1 Year Change	-86.06%
3 Year Change	-84.08%
5 Year Change	n/a
Change since IPO	-87.08%

Recent News & Updates

Jun 16

The Prognosis For Personalis

Today, we profile Personalis, a small cancer genomics testing firm. The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash. 2022 is a transition year for the company in many ways. An investment analysis follows in the paragraphs below.

Jun 09

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

	PSNL	US Life Sciences	US Market
7D	8.2%	4.5%	1.7%
1Y	-86.1%	-19.0%	-20.4%

Return vs Industry: PSNL underperformed the US Life Sciences industry which returned -17.4% over the past year.

Return vs Market: PSNL underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is PSNL's price volatile compared to industry and market?
PSNL volatility
PSNL Average Weekly Movement	14.1%
Life Sciences Industry Average Movement	11.3%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: PSNL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PSNL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2011	326	John West	https://www.personalis.com

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Personalis Fundamentals Summary

How do Personalis's earnings and revenue compare to its market cap?
PSNL fundamental statistics
Market Cap	US$167.24m
Earnings (TTM)	-US$81.03m
Revenue (TTM)	US$79.84m

2.1x

P/S Ratio

-2.1x

P/E Ratio

Is PSNL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSNL income statement (TTM)
Revenue	US$79.84m
Cost of Revenue	US$51.33m
Gross Profit	US$28.51m
Other Expenses	US$109.54m
Earnings	-US$81.03m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.78
Gross Margin	35.71%
Net Profit Margin	-101.49%
Debt/Equity Ratio	1.2%

How did PSNL perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is PSNL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PSNL?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PSNL. This is calculated by dividing PSNL's market cap by their current preferred multiple.
What is PSNL's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$167.24m

PSNL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PSNL's PS Ratio compare to its peers?

PSNL PS Ratio vs Peers

The above table shows the PS ratio for PSNL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	7.5x
CGEN Compugen	25.9x	89.2%	US$167.7m
CDXC ChromaDex	1.8x	22.5%	US$122.6m
LAB Standard BioTools	1.1x	n/a	US$139.1m
HBIO Harvard Bioscience	1.3x	11.7%	US$155.5m
PSNL Personalis	2.1x	28.2%	US$167.2m

Forward PS

Price-To-Sales vs Peers: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (7.5x).

Price to Earnings Ratio vs Industry

How does PSNL's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Life Sciences industry average (5.2x)

Price to Sales Ratio vs Fair Ratio

What is PSNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PSNL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.1x
Fair PS Ratio	4.7x

Price-To-Sales vs Fair Ratio: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Share Price vs Fair Value

What is the Fair Price of PSNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PSNL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PSNL's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSNL's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Personalis forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

1.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSNL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSNL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSNL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSNL's revenue (28.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: PSNL's revenue (28.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PSNL is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Personalis performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-36.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSNL is currently unprofitable.

Growing Profit Margin: PSNL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PSNL is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.

Accelerating Growth: Unable to compare PSNL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSNL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).

Return on Equity

High ROE: PSNL has a negative Return on Equity (-28.26%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Personalis's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PSNL's short term assets ($294.0M) exceed its short term liabilities ($39.8M).

Long Term Liabilities: PSNL's short term assets ($294.0M) exceed its long term liabilities ($54.1M).

Debt to Equity History and Analysis

Debt Level: PSNL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PSNL's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSNL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSNL has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 56.4% each year.

Discover healthy companies

Dividend

What is Personalis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSNL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSNL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSNL has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure

CEO

John West (64 yo)

10.83yrs

Tenure

US$4,929,200

Compensation

Mr. John Stephen West is Co-Founder of Personalis, Inc and has been its Chief Executive Officer since August 3, 2011. Mr. West has been President and Director of Personalis, Inc since August 2011. He has b...

CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD4.93M) is above average for companies of similar size in the US market ($USD1.75M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: PSNL's management team is considered experienced (2.2 years average tenure).

Board Members

Experienced Board: PSNL's board of directors are considered experienced (3.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: PSNL insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/28 00:00
End of Day Share Price	2022/06/28 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31